179 related articles for article (PubMed ID: 15826718)
1. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression.
Yoshiji H; Kuriyama S; Noguchi R; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Masaki T; Fukui H
J Hepatol; 2005 May; 42(5):687-93. PubMed ID: 15826718
[TBL] [Abstract][Full Text] [Related]
2. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis.
Noguchi R; Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Mitoro A; Tsujinoue H; Imazu H; Masaki T; Fukui H
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6038-45. PubMed ID: 14676130
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
Yoshiji H; Kuriyama S; Noguchi R; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Akahane T; Asada K; Tsujimoto T; Uemura M; Fukui H
Oncol Rep; 2006 Jan; 15(1):155-9. PubMed ID: 16328049
[TBL] [Abstract][Full Text] [Related]
4. Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y
Oncol Rep; 2005 Mar; 13(3):491-5. PubMed ID: 15706423
[TBL] [Abstract][Full Text] [Related]
5. Suppression of renin-angiotensin system attenuates hepatocarcinogenesis via angiogenesis inhibition in rats.
Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
Anticancer Res; 2005; 25(5):3335-40. PubMed ID: 16101147
[TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
Yanase K; Yoshiji H; Ikenaka Y; Noguchi R; Kitade M; Kaji K; Yoshii J; Namisaki T; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
Oncol Rep; 2007 Feb; 17(2):441-6. PubMed ID: 17203185
[TBL] [Abstract][Full Text] [Related]
7. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.
Yoshiji H; Noguchi R; Toyohara M; Ikenaka Y; Kitade M; Kaji K; Yamazaki M; Yamao J; Mitoro A; Sawai M; Yoshida M; Fujimoto M; Tsujimoto T; Kawaratani H; Uemura M; Fukui H
J Hepatol; 2009 Aug; 51(2):315-21. PubMed ID: 19501932
[TBL] [Abstract][Full Text] [Related]
8. The copper-chelating agent, trientine, attenuates liver enzyme-altered preneoplastic lesions in rats by angiogenesis suppression.
Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Yanase K; Namisaki T; Yamazaki M; Tsujinoue H; Imazu H; Fukui H
Oncol Rep; 2003; 10(5):1369-73. PubMed ID: 12883709
[TBL] [Abstract][Full Text] [Related]
9. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells.
Yoshiji H; Yoshii J; Ikenaka Y; Noguchi R; Yanase K; Tsujinoue H; Imazu H; Fukui H
Int J Oncol; 2002 Jun; 20(6):1227-31. PubMed ID: 12012003
[TBL] [Abstract][Full Text] [Related]
10. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.
Yoshiji H; Kuriyama S; Kawata M; Yoshii J; Ikenaka Y; Noguchi R; Nakatani T; Tsujinoue H; Fukui H
Clin Cancer Res; 2001 Apr; 7(4):1073-8. PubMed ID: 11309359
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
Yoshiji H; Kuriyama S; Fukui H
Tumour Biol; 2002; 23(6):348-56. PubMed ID: 12677092
[TBL] [Abstract][Full Text] [Related]
12. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial.
Yoshiji H; Noguchi R; Ikenaka Y; Kaji K; Aihara Y; Yamazaki M; Yamao J; Toyohara M; Mitoro A; Sawai M; Yoshida M; Morioka C; Fujimoto M; Uemura M; Fukui H
Oncol Rep; 2011 Dec; 26(6):1547-53. PubMed ID: 21874260
[TBL] [Abstract][Full Text] [Related]
13. Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
Nasr M; Selima E; Hamed O; Kazem A
Eur J Pharmacol; 2014 Jan; 723():267-75. PubMed ID: 24291100
[TBL] [Abstract][Full Text] [Related]
14. [Clinical application of vitamin K for hepatocellular carcinoma].
Mizuta T; Ozaki I
Clin Calcium; 2007 Nov; 17(11):1693-9. PubMed ID: 17982189
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats.
Yoshiji H; Yoshii J; Ikenaka Y; Noguchi R; Tsujinoue H; Nakatani T; Imazu H; Yanase K; Kuriyama S; Fukui H
J Hepatol; 2002 Jul; 37(1):22-30. PubMed ID: 12076858
[TBL] [Abstract][Full Text] [Related]
16. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
Wu XZ
Neoplasma; 2008; 55(6):472-81. PubMed ID: 18999874
[TBL] [Abstract][Full Text] [Related]
17. Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats.
Yoshiji H; Kuriyama S; Noguchi R; Ikenaka Y; Yoshii J; Yanase K; Namisaki T; Kitade M; Yamazaki M; Asada K; Akahane T; Tsujimoto T; Uemura M; Fukui H
Int J Mol Med; 2006 May; 17(5):899-904. PubMed ID: 16596278
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats.
Yoshiji H; Noguchi R; Kaji K; Ikenaka Y; Shirai Y; Namisaki T; Kitade M; Tsujimoto T; Kawaratani H; Fukui H
J Gastroenterol; 2010 Apr; 45(4):443-50. PubMed ID: 19941011
[TBL] [Abstract][Full Text] [Related]
19. Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development.
Yoshiji H; Kuriyama S; Noguchi R; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Tsujinoue H; Fukui H
Liver Int; 2005 Feb; 25(1):153-61. PubMed ID: 15698413
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Kaji K; Yoshiji H; Kitade M; Ikenaka Y; Noguchi R; Shirai Y; Aihara Y; Namisaki T; Yoshii J; Yanase K; Tsujimoto T; Kawaratani H; Fukui H
Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1094-104. PubMed ID: 21372165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
